What Happened?
Cambridge, MA-based Inozyme Appointed Axel Bolte as Chief Executive Officer
About the Company
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
About the Person
Axel Bolte is Chief Executive Officer at Inozyme. Previously, Axel held various senior HR leadership roles in the industry.
Info Source
News
Short Profile